Compare Stocks: COYA, ARCT, PRTA, and KYTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$14.38 -2.1%	$10.60	$5.50 ▼ $24.17	$408.72M	2.48	614,386 shs	1.07 million shs
COYA Coya Therapeutics	$5.30 +7.1%	$4.61	$3.71 ▼ $7.75	$124.34M	0.61	183,774 shs	334,102 shs
KYTX Kyverna Therapeutics	$7.51 +5.5%	$7.85	$5.30 ▼ $13.67	$464.42M	1.98	904,119 shs	833,223 shs
PRTA Prothena	$8.99 +5.6%	$8.91	$7.73 ▼ $11.80	$470.65M	-0.33	505,821 shs	388,329 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-8.36%	-3.92%	+9.22%	+107.49%	-28.20%
COYA Coya Therapeutics	+1.23%	+6.68%	+1.64%	-8.16%	-10.00%
KYTX Kyverna Therapeutics	-0.14%	-3.78%	-15.44%	-15.54%	+22.76%
PRTA Prothena	-0.82%	-3.95%	-9.95%	-10.89%	+5.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$14.38 -2.1%	$10.60	$5.50 ▼ $24.17	$408.72M	2.48	614,386 shs	1.07 million shs
COYA Coya Therapeutics	$5.30 +7.1%	$4.61	$3.71 ▼ $7.75	$124.34M	0.61	183,774 shs	334,102 shs
KYTX Kyverna Therapeutics	$7.51 +5.5%	$7.85	$5.30 ▼ $13.67	$464.42M	1.98	904,119 shs	833,223 shs
PRTA Prothena	$8.99 +5.6%	$8.91	$7.73 ▼ $11.80	$470.65M	-0.33	505,821 shs	388,329 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-8.36%	-3.92%	+9.22%	+107.49%	-28.20%
COYA Coya Therapeutics	+1.23%	+6.68%	+1.64%	-8.16%	-10.00%
KYTX Kyverna Therapeutics	-0.14%	-3.78%	-15.44%	-15.54%	+22.76%
PRTA Prothena	-0.82%	-3.95%	-9.95%	-10.89%	+5.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.60	Moderate Buy	$23.00	63.58% Upside
COYA Coya Therapeutics	2.71	Moderate Buy	$15.33	194.25% Upside
KYTX Kyverna Therapeutics	2.60	Moderate Buy	$30.00	309.22% Upside
PRTA Prothena	2.75	Moderate Buy	$24.57	176.08% Upside

Current Analyst Ratings Breakdown

Latest COYA, ARCT, PRTA, and KYTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/15/2026	COYA Coya Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
9/9/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	ARCT Arcturus Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$41.00
8/24/2026	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	COYA Coya Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/12/2026	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
8/11/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	PRTA Prothena	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/24/2026	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00
7/17/2026	ARCT Arcturus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$18.72M	21.34	N/A	N/A	$7.53 per share	1.87
COYA Coya Therapeutics	$7.95M	15.38	N/A	N/A	$2.06 per share	2.53
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$3.85 per share	N/A
PRTA Prothena	$54.53M	8.54	N/A	N/A	$5.21 per share	1.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
COYA Coya Therapeutics	-$21.23M	-$1.07	N/A	N/A	N/A	-270.22%	-52.05%	-46.34%	11/11/2026 (Estimated)
KYTX Kyverna Therapeutics	-$161.31M	-$2.94	N/A	N/A	N/A	N/A	-81.92%	-63.74%	11/11/2026 (Estimated)
PRTA Prothena	-$244.09M	-$0.84	N/A	N/A	3.02	-80.68%	-16.45%	-14.51%	11/5/2026 (Estimated)

Latest COYA, ARCT, PRTA, and KYTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.6783	-$0.63	+$0.0483	-$0.63	N/A	N/A
8/11/2026	Q2 2026	COYA Coya Therapeutics	-$0.3457	-$0.28	+$0.0657	-$0.28	$0.13 million	$0.24 million
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/6/2026	Q2 2026	PRTA Prothena	-$0.39	-$0.32	+$0.07	-$0.36	$0.42 million	$1.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	$0.71	5.09%	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
COYA Coya Therapeutics	N/A	13.40	13.40
KYTX Kyverna Therapeutics	0.15	9.06	9.06
PRTA Prothena	N/A	25.05	25.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
COYA Coya Therapeutics	39.75%
KYTX Kyverna Therapeutics	18.08%
PRTA Prothena	97.08%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
COYA Coya Therapeutics	6.10%
KYTX Kyverna Therapeutics	17.60%
PRTA Prothena	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	111	28.42 million	23.36 million	Optionable
COYA Coya Therapeutics	8	23.46 million	22.03 million	Not Optionable
KYTX Kyverna Therapeutics	149	61.84 million	50.96 million	Optionable
PRTA Prothena	67	52.35 million	46.91 million	Optionable

COYA, ARCT, PRTA, and KYTX Headlines

Recent News About These Companies

Prothena (NASDAQ:PRTA) Major Shareholder William Scully Purchases 100,000 Shares

September 22 at 4:22 AM | insidertrades.com

Prothena Corp Public Ltd Insider Bought Shares Worth $843,460, According to a Recent SEC Filing

September 21 at 11:14 PM | marketscreener.comM

William Scully Buys 100,000 Shares of Prothena (NASDAQ:PRTA) Stock

September 21 at 5:07 PM | marketbeat.com

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

September 21 at 1:40 PM | zacks.com

[PRTA] Attention!! Reaching the 'Previous Buy Price' of Big Players Who Sold at the Top! Prothena Dip-Buying Strategy Targeting Chart Pivot Points

September 18, 2026 | note.comN

Prothena Corporation plc (NASDAQ:PRTA) Receives Average Recommendation of "Moderate Buy" from Analysts

September 18, 2026 | marketbeat.com

Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026 | businesswire.com

Prothena (NASDAQ:PRTA) Major Shareholder Purchases 27,000 Shares of Stock

September 4, 2026 | insidertrades.com

Prothena (NASDAQ:PRTA) Major Shareholder Purchases $255,690.00 in Stock

September 3, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Share Price Passes Below Two Hundred Day Moving Average - What's Next?

September 1, 2026 | marketbeat.com

Prothena Corporation plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 24, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Major Shareholder William Scully Purchases 50,000 Shares

August 22, 2026 | insidertrades.com

KMDA or PRTA: Which Is the Better Value Stock Right Now?

August 14, 2026 | zacks.com

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

August 8, 2026 | theglobeandmail.com

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

August 7, 2026 | zacks.com

Prothena: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

August 6, 2026 | businesswire.com

Prothena (NASDAQ:PRTA) Insider Sells $64,897.14 in Stock

July 31, 2026 | insidertrades.com

Prothena to Report Second Quarter 2026 Financial Results on August 6

July 30, 2026 | finance.yahoo.com

PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?

July 9, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, ARCT, PRTA, and KYTX Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$14.38 -0.31 (-2.11%)

Closing price 04:00 PM Eastern

Extended Trading

$14.40 +0.01 (+0.10%)

As of 04:20 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Coya Therapeutics NASDAQ:COYA

$5.30 +0.35 (+7.07%)

Closing price 04:00 PM Eastern

Extended Trading

$5.39 +0.09 (+1.75%)

As of 04:19 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Kyverna Therapeutics NASDAQ:KYTX

$7.51 +0.39 (+5.48%)

Closing price 04:00 PM Eastern

Extended Trading

$7.51 0.00 (0.00%)

As of 04:15 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Prothena NASDAQ:PRTA

$8.99 +0.48 (+5.64%)

Closing price 04:00 PM Eastern

Extended Trading

$8.98 -0.01 (-0.11%)

As of 04:20 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COYA, ARCT, PRTA, and KYTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COYA, ARCT, PRTA, and KYTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COYA, ARCT, PRTA, and KYTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, ARCT, PRTA, and KYTX Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Coya Therapeutics NASDAQ:COYA

Kyverna Therapeutics NASDAQ:KYTX

Prothena NASDAQ:PRTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COYA, ARCT, PRTA, and KYTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COYA, ARCT, PRTA, and KYTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COYA, ARCT, PRTA, and KYTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, ARCT, PRTA, and KYTX Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Coya Therapeutics NASDAQ:COYA

Kyverna Therapeutics NASDAQ:KYTX

Prothena NASDAQ:PRTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools